Fingerprint
Dive into the research topics of 'A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515)'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically